Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 6Neoplasms 3Lung Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pleural Effusion 1Pituitary Diseases 1Pituitary ACTH Hypersecretion 1Obesity 1Myasthenia Gravis 1Motor Activity 1Lymphoma 1Kidney Neoplasms 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Advanced Solid Tumors 1Adenocarcinoma of Lung 1ACTH-Secreting Pituitary Adenoma 1

Interventions

Sunitinib 26Everolimus 20Bevacizumab 19aldesleukin 18Sorafenib 16Nivolumab 16Interleukin-2 14pembrolizumab 13Peripheral Blood Stem Cell Transplantation 13fludarabine phosphate 12Radiotherapy 12Interferon-alpha 12Cyclophosphamide 12Radiosurgery 11Filgrastim 11Blood Specimen Collection 11Ipilimumab 10Gemcitabine 10Axitinib 9Surveys and Questionnaires 7Gene Expression Profiling 7Cryosurgery 7temsirolimus 6pazopanib 6Surgical Procedures, Operative 6durvalumab 5cabozantinib 5atezolizumab 5Mycophenolic Acid 5Immunohistochemistry 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Kidney Neoplasms × Biomarkers × Clear all
NCT01070186 2012-07-31

Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡